Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer

Completed · Phase 3

Conditions studied: Prostate Cancer

In brief

This is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of CASODEX. Patient will receive CASODEX as long as physician feels that he is benefiting from this form of therapy.

Key facts

Study ID

NCT00846976

Run by

AstraZeneca

People needed

101

Starts

1994-12-01

Expected to finish

2013-06-01

Last updated by the study team

2015-01-21

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed adenocarcinoma of the prostate gland
• Patients with advanced prostate cancer
• Adult male over the age of 18 years old
• Normal liver function (AST < 2 x Upper Limit Normal)

You may not qualify if…

• ECOG performance status of 4.
• Previous history or presence of another malignancy other than prostate cancer or treated squamous/basal cell carcinoma of the skin, within the last 5 years.

Where it is running

• Research Site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.